Beam Therapeutics Company Description

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies.

The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.

Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

Country	United States
Founded	2017
Industry	Biological Products, Except Diagnostic Substances
Employees	483
CEO	John Evans

Contact Details

Address: 238 Main Street Cambridge, Delaware 02142 United States
Phone	857 327 8775
Website	beamtx.com

Stock Details

Ticker Symbol	BEAM
Exchange	Mexican Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
John Evans	Chief Executive Officer
Sravan Emany	Chief Financial Officer
Holly Manning	Head of Investor Relations